TGFB1 and systemic sclerosis: The results obtained therefore extend the observations of the previously reported in vitro study of the antifibrotic effects of Bosutinib in SSc dermal fibroblasts [40] to an in vivo transgenic mouse model of TGF-β-mediated tissue fibrosis and overall reinforce the previously stated conclusion that Bosutinib [77] may represent a novel, selective and effective antifibrotic agent for therapy of SSc and other fibrotic disorders.